Navigation Links
Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Melanoma Cancer Clinical Trial
Date:9/24/2009

carboplatin clinical trial for patients with metastatic melanoma, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
2. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
3. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
4. Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 Research and Markets  has ... Abuse Testing Markets (Lab-Based, Professional POC, Home, Employment, ... http://photos.prnewswire.com/prnh/20130307/600769 ... category in IVD testing with competitive participation by ... employers, criminal justice personnel, and sports use drug ...
(Date:8/1/2014)... 1, 2014  VanDeMark Chemical Inc., ... of phosgene and phosgene derivatives in ... has acquired Framochem Kft, a leading European-based manufacturer ... . The purchase unites two ... of the world,s largest, independent manufacturers of products ...
(Date:8/1/2014)... , Aug. 1, 2014 RoundTable ... focused exclusively on the healthcare industry, announced today ... The Lubrizol Corporation ("Lubrizol"). Lubrizol, a Berkshire Hathaway ... and supplies technologies to customers in the global ... transaction were not disclosed. Vesta is ...
Breaking Medicine Technology:Drugs of Abuse Testing Markets (Lab-Based, Professional POC, Home, Employment, Criminal Justice Markets) 2VanDeMark Chemical Inc. Acquires Framochem 2VanDeMark Chemical Inc. Acquires Framochem 3VanDeMark Chemical Inc. Acquires Framochem 4RoundTable Healthcare Partners Announces Sale of Vesta Funding, Inc. to The Lubrizol Corporation 2
(Date:8/1/2014)... York (PRWEB) August 01, 2014 Parker ... the rights of victims injured by defective medical devices ... would be recalling its Ethicon surgical power morcellator devices ... maker sited concerns involving the spread of cancer associated ... report dated July 31, 2014. , Johnson & ...
(Date:8/1/2014)... Aug. 1, 2014 (HealthDay News) -- Almost 140 ... school transportation in the United States. But ... bus-related catastrophes, Dawne Gardner, injury prevention coordinator at ... Center, said in a medical center news release. ... returning to school, it,s important for parents and ...
(Date:8/1/2014)... 01, 2014 The evolving healthcare ... community pharmacies. At ThoughtSpot 2014, AmerisourceBergen and Good ... practices and resources to enhance patient care and ... on critical issues to give independent pharmacists the ... , ThoughtSpot show attendance experienced a nearly ...
(Date:8/1/2014)... 01, 2014 The American Telemedicine ... Harper (R-MS), and Peter Welch (D-VT), for their ... Telehealth Parity Act of 2014, which improves telemedicine ... effort to improve healthcare access and affordability using ... of ATA. "These cost-saving provisions are critical to ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 On Monday, ... California NextGen User Symposium in San Francisco, CA. Now ... at the JW Marriott Union Square hotel. , “We ... get up to speed with ACA compliance issues,” Quirk ... month. The symposium provides attendees guidance with NextGen implementation ...
Breaking Medicine News(10 mins):Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 3Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 4Health News:Expert Offers School Bus Safety Tips 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2
... at the Massachusetts Institute of Technology (MIT) has found ... ability to deform, and squeeze through tiny blood vessels ... the malaria-inducing parasite Plasmodium falciparum. ,The ... called RESA (ring-infected erythrocyte surface antigen), and found that ...
... the capital on Saturday. ,The Nigah Queer ... by many international directors. The films will be followed by ... of the programme is to give voice to the issue ... Code (IPC) is still in existence. Section 377 criminalizes private ...
... It seems that Hollywood hunk Brad Pitt is enjoying parental bliss ... the pregnant Myleene Klass at Cannes, Pitt poured his heart out ... have had your first scan yet? They're mind-blowing. Get ready to ... - it's the best thing that ever happened to me,' the ...
... new scare over soft drinks is in the making following revelations ... and Pepsi Max has the ability to switch off vital ... ,For when parts of DNA are disabled, as it were, it ... such as Parkinson's. ,Concerns centre on the safety of ...
... largest ever Parkinson's disease (PD) clinical trials to determine ... symptom progression of this disorder. ,PD is ... develop tremor, slowness of movements and stiffness of muscles. ... U.S. Currently, there are a number of effective treatments ...
... the way of administering the one effective drug, the ... in the USA, reports say . ,Stroke ... behind heart disease and cancer, killing 150,000 Americans a ... nation $62.7 billion, according to the American Stroke Association. ...
Cached Medicine News:Health News:Why Malaria Parasite Affects Red Blood Cells Deformability Revealed 2Health News:Gay Film Festival Begins in Delhi 2Health News:Soft Drink Additive Could Cause Cell Damage 2Health News:Soft Drink Additive Could Cause Cell Damage 3Health News:Emory Participates in Study to Slow Progression of Parkinson's Disease 2Health News:Lack of Timely Intervention Results in Needless Death Due to Stroke in US 2
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
The Intradyn Tear-Away Introducer Sheath with Spin-Lock offers a secure dilatorsheath connection, a smooth dilatorsheath transition and a clean, even tear....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Medicine Products: